报告人  : Xiang Liu，National Institutes of Health，U.S.

报告时间: 2019年5月7日16:30-17:30

报告地点:生科院四楼大会议室

邀请人  :甘璐 教授 朱艳红 副教授

研究经历11/2018-present: Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health.  Scientist.      03/2011-11/2018: National Institute of Allergy and Infectious Diseases, National Institutes of Health. Research Fellow. 研究方向呼吸道合胞病毒重组疫苗研究及临床前开发 报告摘要Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children. Human parainfluenza viruses (PIVs) are second to RSV as a viral cause of pediatric lower respiratory tract disease. There is no vaccine for RSV and PIVs. We employed PIV1 vector to express RSV fusion protein F. RSV F gene was codon optimized and stabilized in pre-fusion conformation. In addition, the transmembrane domain (TM) and cytoplasmic tail (CT) domain of RSV F was replaced by predicted TMCT domain of PIV1 F to increase the incorporation of RSV F in viral particles. The recombinant viruses were immunogenic and protective in hamsters. These vaccine candidates could serve as primary immunization against PIV1 infection and also boost the immune response to an RSV vaccine that had been administered at an earlier age.